Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes:reproducibility and effect of age, weight, and duration of diabetes by Haidar, Ahmad et al.
OBSERVATIONS
Pharmacokinetics of
Insulin Aspart in
Pump-Treated
SubjectsWith Type 1
Diabetes:
Reproducibility and
EffectofAge,Weight,
and Duration of
Diabetes
Insulin aspart, lispro, or glulisine arerecommended in pump-treated type 1diabetes (T1D). Aspart pharmacoki-
netics has been studied (1), but little is
known about its reproducibility and asso-
ciations with anthropometric and clinical
factors.
We analyzed retrospectively data col-
lected in 70 pump-treated subjects with
T1D, comprising 39 females, 46 young,
withmean (SD) BMI 22.7 (4.2) kg/m2, A1C
8.1% (1.3) (65.3 [14.4] mmol/mol), and
total daily insulin 0.8 (0.3) units/kg/day,
who were undergoing investigations, with
ethical approval, of closed-loop insulin
delivery. Participants/guardians signed
consent/assent as appropriate. Partici-
pants were admitted twice to the research
facility, 1–6 weeks apart, for 15–37 h,
and consumed 1–4 meals accompanied
by prandial insulin aspart. Basal aspart
was delivered using closed-loop insulin
delivery or conventional pump therapy.
Venous blood samples were collected
every 30–60 min to measure plasma in-
sulin (Invitron, Monmouth, U.K.).
From 5,804 plasma insulin mea-
surements, we estimated, using a two-
compartment model, the time-to-peak
plasma insulin concentration (tmax
[min]), the metabolic clearance rate of
insulin (MCR in mL/kg/min), and the
background residual plasma insulin
concentration (mU/L). Results are pre-
sented in Table 1. Sex differences in as-
part kinetics were not observed. Aspart
pharmacokinetics was weakly inﬂuenced
by common clinical and anthropometric
factors, because less than 20% of inter-
subject variability was explained by sex,
BMI, total daily dose, A1C, and diabetes
duration.
We measured tmax comparable to lit-
erature reports (1) but observed higher
inter- and intraindividual variability of
tmax in T1D compared with healthy sub-
jects, with intersubject coefﬁcient of var-
iation 33% vs. 20% and intrasubject
coefﬁcient of variation 27% vs. 15%
(comparison against Heinemann et al.
[2]). Nearly 40% of total variance was
attributed to interoccasion variability,
presumably due to variations in depth
of cannula insertion, insulin site age,
and local tissue perfusion. This consider-
able interoccasion variability suggests
large intrapatient variability in postpran-
dial insulin concentration even when
prandial boluses are identical. A slower
insulin absorption rate was associated
with a higher BMI; the BMI z score did
not alter this relationship in the young.
Comparable ﬁndings using soluble insu-
lin were reported in healthy subjects (3),
but absorption of rapid-acting insulin in
obese type 2 diabetes was not inﬂuenced
by BMI (4).
MCR was highly reproducible. In the
absence of a large bedtime bolus, over-
night plasma insulin is dictated by basal
pump settings. Pump settings are normally
altered infrequently and, because MCR is
reproducible, our data suggest that the
overnight plasma insulin concentration
in pump-treated patients is consistent
between nights and unable to explain
considerable night-to-night blood glucose
variations often observed in T1D. The
background insulin concentration de-
creased with diabetes duration. An ultra-
sensitive assay documented that C-peptide
secretion persists over decades but de-
creaseswith disease duration (5). The back-
ground concentration observed in our data
may reﬂect this residual secretion.
Our data lack standardization of in-
sulin delivery, but we mitigated by the
use of compartment modeling. Limita-
tions are nonstandardized infusion sets,
cannula placement, and age of cannula
site likely increasing variability of ab-
sorption but representative of the stan-
dard clinical practice.
In conclusion, anthropometric and
clinical factors are weakly associated with
aspart pharmacokinetics. Sex does not
affect aspart pharmacokinetics. The basal
plasma insulin concentrations but not
postprandial insulin levels are reproduc-
ible between occasions.
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Table 1—Aspart pharmacokinetics, reproducibility, and correlation with clinical and
anthropometric factors
tmax MCR Ib
Mean (SD) or median (IQR) 66 (22) min 16.8 (7.4) mL/kg/min 4.6 (1.6, 9.7) mU/L
Reproducibility† SD 15 min Coefﬁcient of
variation 15%
SD 4.7 mU/L
Interoccasion variation out
of total variance (%) 37 13 28
Correlations
BMI 0.30* 0.00 20.21
Total daily insulin dose/kg 20.07 20.06 0.26*
Age 0.10 0.14 20.33**
A1C 20.09 0.13 0.10
Duration of diabetes 0.05 0.31‡ 20.38**
Adjusted R2 of the regression
model (%)‡ 13 14 18
Ib, background residual plasma insulin concentration; IQR, interquartile range. †Interoccasion variability.
*P , 0.05. **P , 0.01. ‡Model included sex, BMI, total daily dose, A1C, and duration of diabetes.
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